Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
Antiviral activities
C-nucleoside
Dengue
Hepatitis C
Ribavirin
Zika virus
Journal
Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298
Informations de publication
Date de publication:
15 08 2022
15 08 2022
Historique:
received:
21
04
2022
revised:
23
05
2022
accepted:
25
05
2022
pubmed:
7
6
2022
medline:
29
6
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Ribavirin is an unnatural nucleoside exhibiting broad spectrum of antiviral and antitumor activities, still very widely studied particularly in a repositioning approach. C-triazolyl nucleoside analogues of ribavirin have been synthesized, as well as prodrugs and glycosylated or peptide conjugates to allow a better activity by vectorization into the liver or by facilitating uptake into the cells. The antiviral properties of all synthesized compounds have been evaluated in vitro against two important human viral pathogens belonging to the Flaviviridae family: hepatitis C virus (HCV) and Zika virus (ZIKV). There are no therapeutic options for Zika virus, whereas those available for HCV can be still improved. Our results indicated that compound 2 carrying an N-hydroxy carboxamide function exhibits the most inhibitory activities against both viruses. This compound moderately inhibited the propagation of HCV with an IC
Identifiants
pubmed: 35661850
pii: S0968-0896(22)00250-4
doi: 10.1016/j.bmc.2022.116858
pii:
doi:
Substances chimiques
Antiviral Agents
0
Nucleosides
0
Ribavirin
49717AWG6K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116858Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.